HZNP News and Press, Horizon Therapeutics Public Limited Company From 06/05/23

-- TEPEZZA Phase 4 trial results to be shared in an oral presentation on Saturday, June 17 at 3:30 p.m. CT -- -- Two patients will share their real-world experience living with TED and being treated with TEPEZZA on Friday, June 16 at 10:15 a.m. CT -- Horizon Therapeutics p...

2023-06-01 12:11:01 ET The House Oversight Committee requested an inquiry into Federal Trade Commission Chair Lina Khan, asking for documents related to her charge of the regulator. The probe comes after former Commissioner Christine S. Wilson, the only Republican at the agency, resigne...

2023-06-01 12:00:00 ET Biotech pioneer Amgen (NASDAQ: AMGN) has several key elements of a good dividend stock. The company has raised its payout for 12 straight years, free cash flows have remained steady at a little over 30% of total sales for several years, and its 3.86% annualize...

-- An alysis in The Journal of Neurology, Neurosurgery and Psychiatry demonstrate the direct effect of UPLIZNA on levels of sNFL and sGFAP, two key biomarkers strongly associated with NMOSD attacks and disability -- Horizon Therapeutics plc (Nasdaq: HZNP) today announced the pub...

2023-06-01 05:16:01 ET Summary Baker Brothers' 13F portfolio value increased from $16.65B to $18.38B, with the largest five stakes in Seagen, Incyte, BeiGene, ACADIA Pharma, and Madrigal Pharma. The firm disposed of its stakes in Ascendis Pharma A/S and Horizon Therapeutics, while...

-- Only Sj ögren’s syndrome Phase 2 trial to meet the primary endpoint in both patient population types -- -- Patients with moderate-to-severe systemic disease activity (ESSDAI score ≥5) treated with dazodalibep experienced improvement in their disease activity (6.3...

-- New data illustrate impact of KRYSTEXXA ® (pegloticase) injection with methotrexate to improve patient outcomes and clinical measures for uncontrolled gout -- Horizon Therapeutics plc (Nasdaq: HZNP) today announced new analyses from the MIRROR randomized controlled trial of ...

2023-05-30 15:02:46 ET Summary Iveric bio, Inc., focused on developing treatments for retinal diseases, has announced its acquisition by Astellas Pharma Inc. Iveric bio, Inc. stock trades at a discount of over 5% for an acquisition that is targeted to close in the third calendar q...

2023-05-30 10:30:49 ET Summary Merger arbitrage in mid-2023 faces regulatory hurdles, with agencies attempting to block deals across industries; however, around 70 public companies have been bought out this year. The top 10 M&A stocks held by funds include Horizon Therapeutics...

2023-05-29 05:36:15 ET Summary Amgen's stock has seen a further pullback since it announced an acquisition of Horizon Therapeutics in December. Shares are down by nearly a quarter as the re-rating starts to look interesting with fundamental valuations starting to provide support. ...